Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
Antibodies, Protozoan
/ blood
Antigens, Protozoan
/ immunology
Benin
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G
/ blood
Infant
Infant, Newborn
Longitudinal Studies
Malaria, Falciparum
/ immunology
Male
Plasmodium falciparum
/ immunology
Pregnancy
Protozoan Proteins
/ immunology
Surveys and Questionnaires
Cytophilic IgG
Malaria
Merozoite vaccine candidate antigens
Plasmodium falciparum
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
11 Jun 2019
11 Jun 2019
Historique:
received:
11
03
2019
accepted:
04
06
2019
entrez:
13
6
2019
pubmed:
13
6
2019
medline:
24
8
2019
Statut:
epublish
Résumé
Substantial evidence indicates that cytophilic IgG responses to Plasmodium falciparum merozoite antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluating antibody responses in infants naturally-exposed to malaria will allow to better understand the establishment of anti-malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite candidate antigens. The study was based on parasitological and clinical active follow-up of infants from birth to 18 months of age conducted in the Tori Bossito area of southern Benin. For 399 infants, plasma levels of cytophilic IgG antibodies with specificity for five asexual stage malaria vaccine candidate antigens were determined by ELISA in infants' peripheral blood at 6, 9, 12 and 15 months of age. Multivariate mixed logistic model was used to investigate the association between antibody levels and anti-malarial protection in the trimester following the IgG quantification. Moreover, the concentrations of merozoite antigen-specific IgG were compared between a group of infants apparently able to control asymptomatic malaria infection (CAIG) and a group of infants with no control of malaria infection (Control group (NCIG)). Protective effect of antibodies was also assessed after 15 months of malaria exposure with a Cox regression model adjusted on environmental risk. Cytophilic IgG responses to AMA1, MSP1, MSP2-3D7, MSP2-FC27, MSP3 and GLURP R2 were associated with increasing malarial infection risk in univariate analysis. The multivariate mixed model showed that IgG1 and IgG3 to AMA1 were associated with an increased risk of malarial infection. However infants from CAIG (n = 53) had significantly higher AMA1-, MSP2-FC27-, MSP3-specific IgG1 and AMA1-, MSP1-, MSP2-FC27-, MSP3 and GLURP-R2-specific IgG3 than those from NCIG (n = 183). The latter IgG responses were not associated with protection against clinical malaria in the whole cohort when protective effect is assessed after 15 months of malaria exposition. In this cohort, merozoite antigen-specific cytophilic IgG levels represent a marker of malaria exposure in infants from 6 to 18 months of age. However, infants with resolution of asymptomatic infection (CAIG) seem to have acquired naturally immunity against P. falciparum. This observation is encouraging in the context of the development of multitarget P. falciparum vaccines.
Sections du résumé
BACKGROUND
BACKGROUND
Substantial evidence indicates that cytophilic IgG responses to Plasmodium falciparum merozoite antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluating antibody responses in infants naturally-exposed to malaria will allow to better understand the establishment of anti-malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite candidate antigens.
METHODS
METHODS
The study was based on parasitological and clinical active follow-up of infants from birth to 18 months of age conducted in the Tori Bossito area of southern Benin. For 399 infants, plasma levels of cytophilic IgG antibodies with specificity for five asexual stage malaria vaccine candidate antigens were determined by ELISA in infants' peripheral blood at 6, 9, 12 and 15 months of age. Multivariate mixed logistic model was used to investigate the association between antibody levels and anti-malarial protection in the trimester following the IgG quantification. Moreover, the concentrations of merozoite antigen-specific IgG were compared between a group of infants apparently able to control asymptomatic malaria infection (CAIG) and a group of infants with no control of malaria infection (Control group (NCIG)). Protective effect of antibodies was also assessed after 15 months of malaria exposure with a Cox regression model adjusted on environmental risk.
RESULTS
RESULTS
Cytophilic IgG responses to AMA1, MSP1, MSP2-3D7, MSP2-FC27, MSP3 and GLURP R2 were associated with increasing malarial infection risk in univariate analysis. The multivariate mixed model showed that IgG1 and IgG3 to AMA1 were associated with an increased risk of malarial infection. However infants from CAIG (n = 53) had significantly higher AMA1-, MSP2-FC27-, MSP3-specific IgG1 and AMA1-, MSP1-, MSP2-FC27-, MSP3 and GLURP-R2-specific IgG3 than those from NCIG (n = 183). The latter IgG responses were not associated with protection against clinical malaria in the whole cohort when protective effect is assessed after 15 months of malaria exposition.
CONCLUSION
CONCLUSIONS
In this cohort, merozoite antigen-specific cytophilic IgG levels represent a marker of malaria exposure in infants from 6 to 18 months of age. However, infants with resolution of asymptomatic infection (CAIG) seem to have acquired naturally immunity against P. falciparum. This observation is encouraging in the context of the development of multitarget P. falciparum vaccines.
Identifiants
pubmed: 31185998
doi: 10.1186/s12936-019-2831-x
pii: 10.1186/s12936-019-2831-x
pmc: PMC6560827
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Immunoglobulin G
0
Protozoan Proteins
0
merozoite major surface antigen, Plasmodium
0
Types de publication
Journal Article
Langues
eng
Pagination
194Références
Infect Immun. 1999 May;67(5):2131-7
pubmed: 10225865
Nat Med. 2000 Jun;6(6):689-92
pubmed: 10835687
Infect Immun. 2002 Aug;70(8):4471-6
pubmed: 12117958
Infect Immun. 2004 Nov;72(11):6492-502
pubmed: 15501780
J Infect Dis. 2005 Jan 15;191(2):264-71
pubmed: 15609237
Parasitology. 1992;104 Suppl:S53-69
pubmed: 1589300
Vaccine. 2006 May 8;24(19):4233-46
pubmed: 16111789
Parasite Immunol. 1992 May;14(3):321-37
pubmed: 1625908
Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60
pubmed: 16438676
Vaccine. 2006 Aug 14;24(33-34):5997-6008
pubmed: 16814434
J Immunol. 2007 Mar 1;178(5):3099-106
pubmed: 17312157
Infect Immun. 2008 Feb;76(2):759-66
pubmed: 18070896
Infect Immun. 2008 May;76(5):2240-8
pubmed: 18316390
Malar J. 2008 Jul 29;7:142
pubmed: 18664257
PLoS One. 2009 Oct 27;4(10):e7590
pubmed: 19859562
Hum Vaccin. 2010 Jan;6(1):39-53
pubmed: 20061790
Parasite Immunol. 2010 Feb;32(2):125-34
pubmed: 20070826
PLoS One. 2011;6(9):e24413
pubmed: 21949716
PLoS One. 2012;7(1):e28812
pubmed: 22238582
BMJ Open. 2012 Mar 08;2(2):e000342
pubmed: 22403339
J Immunol. 2013 Jul 15;191(2):795-809
pubmed: 23776179
Vaccine. 2013 Aug 20;31(37):3936-42
pubmed: 23800539
Infect Genet Evol. 2013 Dec;20:16-25
pubmed: 23932959
PLoS One. 2014 Jul 21;9(7):e101737
pubmed: 25047634
PLoS Med. 2014 Jul 29;11(7):e1001685
pubmed: 25072396
J Leukoc Biol. 2014 Dec;96(6):1131-42
pubmed: 25118179
PLoS One. 2014 Sep 19;9(9):e107965
pubmed: 25238160
Infect Immun. 2015 Feb;83(2):646-60
pubmed: 25422270
Immunity. 2015 Mar 17;42(3):580-90
pubmed: 25786180
J Infect Dis. 2015 Nov 1;212(9):1429-38
pubmed: 25883384
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Bull Soc Pathol Exot. 2015 Mar;108(2):94-101
pubmed: 25925805
Open Forum Infect Dis. 2015 Apr 10;2(2):ofv044
pubmed: 26380342
Methods Mol Biol. 2015;1325:131-44
pubmed: 26450385
Malar J. 2015 Oct 15;14:409
pubmed: 26471813
Vaccine. 2016 Jan 2;34(1):160-6
pubmed: 26541134
Clin Vaccine Immunol. 2015 Dec 09;23(2):104-16
pubmed: 26656119
Infect Immun. 2016 Mar 24;84(4):950-963
pubmed: 26787721
FEMS Microbiol Rev. 2016 May;40(3):343-72
pubmed: 26833236
Acta Trop. 2016 Jul;159:111-9
pubmed: 27001144
Sci Rep. 2016 Sep 27;6:33961
pubmed: 27670685
Clin Vaccine Immunol. 2017 Nov 6;24(11):
pubmed: 28877929
PLoS One. 2017 Sep 25;12(9):e0185303
pubmed: 28945794
EBioMedicine. 2017 Nov;25:66-72
pubmed: 29050948
Clin Infect Dis. 2018 Feb 1;66(4):586-593
pubmed: 29401272
Nat Commun. 2019 Feb 5;10(1):610
pubmed: 30723225
Am J Trop Med Hyg. 1984 Mar;33(2):197-203
pubmed: 6370001
Nature. 1982 Jun 17;297(5867):591-3
pubmed: 7045680
Infect Immun. 1995 Oct;63(10):4034-8
pubmed: 7558316
Parasitology. 1976 Apr;72(2):149-62
pubmed: 817249
Parasite Immunol. 1995 Sep;17(9):493-501
pubmed: 8552419
Biometrics. 1995 Dec;51(4):1570-8
pubmed: 8589241
J Infect Dis. 1996 Mar;173(3):765-9
pubmed: 8627050
Am J Trop Med Hyg. 1996 May;54(5):449-57
pubmed: 8644897
Am J Trop Med Hyg. 1998 Feb;58(2):211-9
pubmed: 9502606